Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 136

1.

On the path to 2025: understanding the Alzheimer's disease continuum.

Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B.

Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5. Review.

2.

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.

Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Weiner MW, Green RC, Toga AW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

BMC Med Genomics. 2017 May 24;10(Suppl 1):29. doi: 10.1186/s12920-017-0267-0.

3.

Randomized controlled trials in mild cognitive impairment: Sources of variability.

Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS; Alzheimer's Disease Neuroimaging Initiative (ADNI) and Foundation for NIH (FNIH) Biomarkers Consortium AD MCI Placebo Data Analysis Project Team.

Neurology. 2017 May 2;88(18):1751-1758. doi: 10.1212/WNL.0000000000003907. Epub 2017 Apr 5.

4.

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.

Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS.

J Neuroinflammation. 2017 Jan 3;14(1):1. doi: 10.1186/s12974-016-0779-0.

5.

Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.

Sokolow S, Li X, Chen L, Taylor KD, Rotter JI, Rissman RA, Aisen PS, Apostolova LG.

J Alzheimers Dis. 2017;56(1):229-237. doi: 10.3233/JAD-160562.

6.

Drug development in Alzheimer's disease: the path to 2025.

Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P.

Alzheimers Res Ther. 2016 Sep 20;8:39. doi: 10.1186/s13195-016-0207-9. Review.

7.

Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease.

Nho K, Horgusluoglu E, Kim S, Risacher SL, Kim D, Foroud T, Aisen PS, Petersen RC, Jack CR Jr, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Saykin AJ; ADNI.

BMC Med Genomics. 2016 Aug 12;9 Suppl 1:30. doi: 10.1186/s12920-016-0190-9.

8.

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.

Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS.

Alzheimers Res Ther. 2016 Jun 30;8:25. doi: 10.1186/s13195-016-0194-x.

9.

Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial.

Sano M, Aisen PS, Andrews HF, Tsai WY, Lai F, Dalton AJ; International Down Syndrome and Alzheimer's Disease Consortium.

Neurology. 2016 May 31;86(22):2071-6. doi: 10.1212/WNL.0000000000002714. Epub 2016 May 4.

10.

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 May 17;86(20):1887-96. doi: 10.1212/WNL.0000000000002683. Epub 2016 Apr 15.

11.

Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials.

Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA.

Alzheimers Dement. 2016 May;12(5):631-2. doi: 10.1016/j.jalz.2016.04.001. No abstract available.

12.

Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.

Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR Jr, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2016 Jun 1;73(6):721-32. doi: 10.1001/jamaneurol.2016.0580.

13.

A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).

Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS.

J Prev Alzheimers Dis. 2015 Dec 1;2(4):227-241.

14.

Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.

Aisen PS.

J Prev Alzheimers Dis. 2015;2(2):82-84. No abstract available.

15.

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA.

Front Behav Neurosci. 2015 Sep 14;9:239. doi: 10.3389/fnbeh.2015.00239. eCollection 2015.

16.

CAP--advancing the evaluation of preclinical Alzheimer disease treatments.

Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S.

Nat Rev Neurol. 2016 Jan;12(1):56-61. doi: 10.1038/nrneurol.2015.177. Epub 2015 Sep 29. Review.

17.

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2015 Oct 20;85(16):1383-91. doi: 10.1212/WNL.0000000000002035. Epub 2015 Sep 11.

18.

GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.

Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, Aisen PS, Petersen RC, Jack CR Jr, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Brain. 2015 Oct;138(Pt 10):3076-88. doi: 10.1093/brain/awv231. Epub 2015 Aug 11.

19.

Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia.

Sacuiu S, Insel PS, Mueller S, Tosun D, Mattsson N, Jack CR Jr, DeCarli C, Petersen R, Aisen PS, Weiner MW, Mackin RS; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2016 Feb;24(2):126-35. doi: 10.1016/j.jagp.2015.03.006. Epub 2015 Mar 30.

20.

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, Thompson PM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):865-84. doi: 10.1016/j.jalz.2015.04.005. Review.

Supplemental Content

Loading ...
Support Center